Seroprevalence of hepatitis A in children living in Zonguldak, Turkey [Zonguldak'ta yanşayan çocuklarda hepatit A seroprevlansi]

In order to detect hepatitis A seroprevalence in our patient population the prevalence of antibodies to hepatitis A virus (HAV) was investigated in 257 children (56.4% males) who applied to Zonguldak Karaelmas University Hospital for various reasons between January 2001 and April 2002. Total anti-HAV seropositivity was 13.6%. When age groups were considered, it was 8.5%, 11.3% and 21.7% for ages 1-5, 6-10 and 11-16, respectively. The prevalance rates obtained in our study were lower when compared with previous studies performed in other regions, probably depending on high socio-economical status in our region. Increase of total anti-HAV level with age makes us think that crowded classrooms and inadequate hygienic conditions enhance viral contamination. So appropriate time for vaccination should be after 1st year of life, when passive antibodies from mother disappear, and before 5th year, just before school age.

Yazar Demirel F.
Ünalacak M.
Sögüt A.
Ermiş B.
Yüksel B.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/7494
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı SENDROM
Dergi Cilt Bilgisi 16
Dergi Sayısı 7
Sayfalar 70 - 72
Yayın Yılı 2004
Eser Adı
[dc.title]
Seroprevalence of hepatitis A in children living in Zonguldak, Turkey [Zonguldak'ta yanşayan çocuklarda hepatit A seroprevlansi]
Yazar
[dc.contributor.author]
Demirel F.
Yazar
[dc.contributor.author]
Ünalacak M.
Yazar
[dc.contributor.author]
Sögüt A.
Yazar
[dc.contributor.author]
Ermiş B.
Yazar
[dc.contributor.author]
Yüksel B.
Yayın Yılı
[dc.date.issued]
2004
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
In order to detect hepatitis A seroprevalence in our patient population the prevalence of antibodies to hepatitis A virus (HAV) was investigated in 257 children (56.4% males) who applied to Zonguldak Karaelmas University Hospital for various reasons between January 2001 and April 2002. Total anti-HAV seropositivity was 13.6%. When age groups were considered, it was 8.5%, 11.3% and 21.7% for ages 1-5, 6-10 and 11-16, respectively. The prevalance rates obtained in our study were lower when compared with previous studies performed in other regions, probably depending on high socio-economical status in our region. Increase of total anti-HAV level with age makes us think that crowded classrooms and inadequate hygienic conditions enhance viral contamination. So appropriate time for vaccination should be after 1st year of life, when passive antibodies from mother disappear, and before 5th year, just before school age.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
tur
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1016-5134
İlk Sayfa Sayısı
[dc.identifier.startpage]
70
Son Sayfa Sayısı
[dc.identifier.endpage]
72
Dergi Adı
[dc.relation.journal]
SENDROM
Dergi Sayısı
[dc.identifier.issue]
7
Dergi Cilt Bilgisi
[dc.identifier.volume]
16
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/7494
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
116
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
13 Temmuz 2024 17:59
Google Kontrol
Tıklayınız
antibodies anti-HAV before hepatitis region Increase status socio-economical depending probably regions performed studies previous compared conditions school disappear mother passive should crowded vaccination appropriate contamination enhance hygienic inadequate classrooms obtained reasons various Hospital University Karaelmas
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms